• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Act-Hib
    / Medici

    Active Ingredient

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Pre-filled Syringe (solution for injection)

    1 X 0.5 ml

    full basket chart 9619

    Related information


    – Before 6 months of age, 3 successive doses of 0.5 ml administered one or two months apart, followed by a booster injection (fourth dose) one year after the third injection.
    – Between 6 and 12 months of age, 2 doses of 0.5 ml administered one month apart, followed by a booster injection (0.5 ml) at 18 months of age.
    – From 1 to 5 years of age, a single dose of 0.5 ml.
    For contact cases: in the event of contact with a case of invasive Haemophilus influenzae type b disease (family or childcare), vaccination should be implemented according to the schedule for the contact case’s age.
    The index case should also be vaccinated.
    Method of Administration: Intramuscular or deep subcutaneous route.
    The recommended injection sites are the antero-lateral aspect of the thigh (middle third) for infants and toddlers and the deltoid region for older children.
    Do not inject by the intravascular route.


    This vaccine is indicated for the prevention of Haemophilus influenzae type b invasive infections (meningitis, septicaemia, cellulitis, arthritis, epiglottitis, etc.) in children from the age of 2 months.
    This vaccine does not provide protection against infections due to other types of Haemophilus influenzae or against cases of meningitis of other origins.
    Under no circumstances can the tetanus protein contained in this vaccine be used to replace the usual tetanus vaccination.


    Known hypersensitivity to one of the components of the vaccine, in particular the tetanus protein, or experienced after a previous injection of a Haemophilus influenzae type b conjugate vaccine.

    Special Precautions

    Do not inject by the intravascular route: make sure that the needle does not penetrate a blood vessel.
    In case of fever or acute illness, vaccination should be postponed.
    As with any injectable vaccine liable to induce a potential immediate anaphylactic reaction, an appropriate medical treatment should be available.
    Children with congenital or acquired immunodeficiency may be vaccinated, keeping in mind that, depending on the state of their immune system, their immune response will be lesser or greater. In children under immunosuppressive treatment (corticotherapy, antimitotic chemotherapy, etc.), it is recommended to postpone vaccination until the end of the treatment.
    The potential risk of apnoea and the need for respiratory monitoring for 48-72 h should be considered when administering the primary immunisation series to very premature infants (born ≤28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity.
    As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.

    Side Effects

    See prescribing information for full details.

    Drug interactions

    This vaccine may be administered simultaneously with another, such as the other recommended vaccines (against diphtheria, tetanus, pertussis, poliomyelitis, measles, mumps and rubella, provided that 2 injection sites are used.

    Sanofi Pasteur